Cash on Hand for Vertex Pharmaceuticals (VRTX)
According to Vertex Pharmaceuticals's latest reported financial statements, the company's latest reported cash and short-term investments is $6.61B USD. Cash on hand here is cash, cash equivalents, and short-term investments reported at the end of each period — the most liquid assets on the balance sheet. Compare with total debt for a net cash/debt picture and with total assets for the share of assets held in cash.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
Currently viewingCash on HandSwitch metric
Latest period
$6.61B
YoY change
+8.1%
5Y CAGR
-0.1%
Peak year (2023)
$11.22B
Latest annual
$6.61B
Cash on Hand history chart for Vertex Pharmaceuticals (VRTX) from 1990 to 2025
Cash on Hand history table for Vertex Pharmaceuticals (VRTX) from 1990 to 2025
| Fiscal year | Period ended | Reported | Cash on Hand | YoY |
|---|---|---|---|---|
| 2025 | $6.61B | +8.1% | ||
| 2024 | $6.12B | -45.5% | ||
| 2023 | $11.22B | +4.1% | ||
| 2022 | $10.78B | +43.2% | ||
| 2021 | $7.52B | +13.0% | ||
| 2020 | $6.66B | +74.9% | ||
| 2019 | $3.81B | +20.2% | ||
| 2018 | $3.17B | +51.7% | ||
| 2017 | $2.09B | +45.6% | ||
| 2016 | $1.43B | +37.6% | ||
| 2015 | $1.04B | -24.8% | ||
| 2014 | $1.39B | -5.3% | ||
| 2013 | $1.47B | +10.9% | ||
| 2012 | $1.32B | +36.4% | ||
| 2011 | $968.92M | -6.1% | ||
| 2010 | $1.03B | -19.7% | ||
| 2009 | $1.28B | +54.4% | ||
| 2008 | $832.10M | +80.5% | ||
| 2007 | $460.87M | -34.6% | ||
| 2006 | $704.63M | +95.1% | ||
| 2005 | $361.16M | -6.5% | ||
| 2004 | $386.25M | -33.8% | ||
| 2003 | $583.16M | -8.2% | ||
| 2002 | $634.98M | -14.6% | ||
| 2001 | $743.20M | +61.6% | ||
| 2000 | $459.92M | +144.9% | ||
| 1999 | $187.80M | +676.0% | ||
| 1998 | $24.20M | -66.2% | ||
| 1997 | $71.50M | +104.9% | ||
| 1996 | $34.90M | +22.9% | ||
| 1995 | $28.40M | -60.3% | ||
| 1994 | $71.60M | +150.3% | ||
| 1993 | $28.60M | +146.6% | ||
| 1992 | $11.60M | -58.0% | ||
| 1991 | $27.60M | +527.3% | ||
| 1990 | $4.40M | — |
Cash on Hand values are taken from Vertex Pharmaceuticals's reported balance sheets (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
2025's annual cash and short-term investments for Vertex Pharmaceuticals (VRTX) came in at $6.61B – grew 8.1% year-over-year.
Vertex Pharmaceuticals cash and short-term investments compound annual growth for the 2020–2025 (5 years) window is -0.1%, with a net decline across the window.
Vertex Pharmaceuticals cash and short-term investments peaked at $11.22B in 2023; the latest annual figure is $6.61B in 2025 (41.1% below peak).
The highest annual cash and short-term investments of $11.22B was reported in 2023. The lowest in the available history was $4.40M in 1990.
Vertex Pharmaceuticals (VRTX) sits 7th of 8 Healthcare peers we track on this metric, against a peer median of $11.85B.
Vertex Pharmaceuticals Cash on Hand by Year
Vertex Pharmaceuticals Cash on Hand 2025: $6.61B
Vertex Pharmaceuticals cash and short-term investments in 2025 was $6.61B, grew 8.1% from 2024.
Vertex Pharmaceuticals Cash on Hand 2024: $6.12B
Vertex Pharmaceuticals cash and short-term investments in 2024 was $6.12B, plunged 45.5% below 2023.
Vertex Pharmaceuticals Cash on Hand 2023: $11.22B
Vertex Pharmaceuticals cash and short-term investments in 2023 was $11.22B, edged up 4.1% from 2022. This figure represents the highest annual value in the available history.
Vertex Pharmaceuticals Cash on Hand 2022: $10.78B
Vertex Pharmaceuticals cash and short-term investments in 2022 was $10.78B, surged 43.2% from 2021.
Vertex Pharmaceuticals Cash on Hand 2021: $7.52B
Vertex Pharmaceuticals cash and short-term investments in 2021 was $7.52B.
See more financial history for Vertex Pharmaceuticals (VRTX).
Sector peers — Cash on Hand
Companies in the same sector as Vertex Pharmaceuticals, ranked by their latest cash and short-term investments.
| Company | Cash on Hand | Sector |
|---|---|---|
| UnitedHealth Group Incorporated (UNH) | $28.12B | Healthcare |
| Novo Nordisk A/S (NVO) | $26.96B | Healthcare |
| Johnson & Johnson (JNJ) | $20.10B | Healthcare |
| Merck & Co., Inc. (MRK) | $14.56B | Healthcare |
| Amgen Inc. (AMGN) | $9.13B | Healthcare |
| Eli Lilly and Company (LLY) | $7.27B | Healthcare |
| AstraZeneca PLC (AZN) | $5.74B | Healthcare |
| AbbVie Inc. (ABBV) | $5.26B | Healthcare |
Frequently asked questions
What is Vertex Pharmaceuticals's cash and short-term investments?
- Latest reported cash and short-term investments for Vertex Pharmaceuticals (VRTX) is $6.61B (period ending December 31, 2025).
How has Vertex Pharmaceuticals cash and short-term investments changed year-over-year?
- Vertex Pharmaceuticals (VRTX) cash and short-term investments changed +8.1% year-over-year on the latest annual filing.
What is the long-term growth rate of Vertex Pharmaceuticals cash and short-term investments?
- Vertex Pharmaceuticals (VRTX) cash and short-term investments compound annual growth rate is -0.1% over the most recent 5 years available.
When did Vertex Pharmaceuticals cash and short-term investments hit its highest annual value?
- Vertex Pharmaceuticals cash and short-term investments reached its highest annual value of $11.22B in 2023.
What was Vertex Pharmaceuticals cash and short-term investments in 2024?
- Vertex Pharmaceuticals (VRTX) cash and short-term investments in 2024 was $6.12B.
What was Vertex Pharmaceuticals cash and short-term investments in 2025?
- Vertex Pharmaceuticals (VRTX) cash and short-term investments in 2025 was $6.61B.
Metrics overview
Pick a metric for charts, filings, and peers — each row shows the latest TTM or annual value with year-over-year change.
Explore more
VRTX Overview
Company profile, financial tools, and key metrics
VRTX Revenue Counter
Earns $381.74 every second. See per minute, hour, and day.
VRTX Earnings Counter
Earns $125.36 per second net profit. See per minute, hour, and day.
VRTX Economic Scale
Exceeds Somalia, Fed. Rep.'s GDP. Compare with world economies.
VRTX What If Invested
What if you had invested $1,000? See historical returns from any date.
VRTX How It Makes Money
Discover visual breakdown of $12.04B in revenue — where it comes from and where it goes.
VRTX Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
VRTX Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
VRTX Daily Price Character
Explosive · 48.3% historical win rate (green days). Streaks & record days.
VRTX Buybacks
1.75% TTM buyback yield. Shareholder yield & SBC comparison.
VRTX Stock Split History
1 split on record. Dates, ratios, and cumulative multiple.